180 Life Sciences (ATNF) Competitors $1.98 0.00 (0.00%) As of 10/13/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. GNTA, ACRV, IMMX, DRRX, ELYM, BRNS, ICCC, CELU, CUE, and KPTIShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Genenta Science (GNTA), Acrivon Therapeutics (ACRV), Immix Biopharma (IMMX), DURECT (DRRX), Eliem Therapeutics (ELYM), Barinthus Biotherapeutics (BRNS), ImmuCell (ICCC), Celularity (CELU), Cue Biopharma (CUE), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors Genenta Science Acrivon Therapeutics Immix Biopharma DURECT Eliem Therapeutics Barinthus Biotherapeutics ImmuCell Celularity Cue Biopharma Karyopharm Therapeutics 180 Life Sciences (NASDAQ:ATNF) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Which has preferable valuation & earnings, ATNF or GNTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$6.17M-$15.07-0.13Genenta ScienceN/AN/A-$9.64MN/AN/A Do insiders & institutionals hold more shares of ATNF or GNTA? 4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 38.2% of 180 Life Sciences shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ATNF or GNTA more profitable? Genenta Science's return on equity of 0.00% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -141.25% -80.77% Genenta Science N/A N/A N/A Which has more risk and volatility, ATNF or GNTA? 180 Life Sciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Does the media refer more to ATNF or GNTA? In the previous week, Genenta Science had 4 more articles in the media than 180 Life Sciences. MarketBeat recorded 4 mentions for Genenta Science and 0 mentions for 180 Life Sciences. Genenta Science's average media sentiment score of 0.64 beat 180 Life Sciences' score of 0.00 indicating that Genenta Science is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Genenta Science Positive Do analysts rate ATNF or GNTA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryGenenta Science beats 180 Life Sciences on 6 of the 8 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.96M$3.36B$6.05B$10.52BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-0.1321.9085.0527.24Price / SalesN/A476.87595.29234.24Price / CashN/A46.9537.5761.53Price / Book0.6810.4312.676.74Net Income-$6.17M-$52.58M$3.32B$276.59M7 Day Performance-15.02%-1.55%-1.34%-0.47%1 Month Performance-22.35%12.96%8.11%7.47%1 Year Performance30.26%15.43%78.90%34.58% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life SciencesN/A$1.98flatN/A+45.6%$11.96MN/A-0.137Gap UpGNTAGenenta Science0.9189 of 5 stars$3.22-2.4%N/A-46.3%$60.36MN/A0.007ACRVAcrivon Therapeutics2.4728 of 5 stars$1.91flat$15.00+685.3%-76.0%$60.08MN/A-0.8558Gap DownIMMXImmix Biopharma3.3447 of 5 stars$2.24+8.7%$8.00+257.1%+79.7%$59.40MN/A-2.919News CoverageGap DownHigh Trading VolumeDRRXDURECT1.1281 of 5 stars$1.91flatN/AN/A$59.31M$1.66M-19.1080ELYMEliem TherapeuticsN/A$1.98-2.9%N/A-63.2%$58.91MN/A-3.749Gap UpHigh Trading VolumeBRNSBarinthus Biotherapeutics2.265 of 5 stars$1.57+8.6%$3.00+91.1%+16.2%$58.85M$14.97M-0.91107Analyst ForecastGap UpICCCImmuCell1.1268 of 5 stars$6.35+0.6%N/A+82.6%$57.08M$26.49M33.4270Gap UpCELUCelularity2.0388 of 5 stars$2.08-2.3%$6.00+188.5%-18.1%$56.85M$54.22M-0.65220News CoverageCUECue Biopharma2.4978 of 5 stars$0.73-0.2%N/A-34.1%$56.03M$8.29M-1.3060Positive NewsAnalyst ForecastKPTIKaryopharm Therapeutics4.0373 of 5 stars$6.16-3.4%$34.00+451.9%-54.7%$55.32M$145.24M-0.42380Analyst UpgradeAnalyst Revision Related Companies and Tools Related Companies GNTA Competitors ACRV Competitors IMMX Competitors DRRX Competitors ELYM Competitors BRNS Competitors ICCC Competitors CELU Competitors CUE Competitors KPTI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
